Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
– AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment of patients with solid tumors.
– The collective preclinical data indicate that AMX-818 is effective in driving anti-tumor responses, yet has significantly lower toxicity than its unmasked HER2 TCE counterpart. This profile is enabled by proprietary protease-releasable masking technology that is preferentially cleaved off in the tumor microenvironment to yield active drug.
– Amunix expects to file a Clinical Trial Application (CTA) for AMX-818 by the end of 2021.
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, CA; October 7, 2021 – Amunix Pharmaceuticals, Inc. (Amunix), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients suffering from cancer, today announced that preclinical data from its lead program, AMX-818 (HER2-XPAT), were presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. The collective data indicate that AMX-818 is effective in driving anti-tumor responses, yet has significantly lower toxicity than its unmasked HER2 TCE counterpart. AMX-818 is largely stable in plasma and healthy tissue, yet efficiently cleaved to yield an active TCE in the tumor microenvironment. Amunix expects to file a CTA for AMX-818 by the end of 2021.
“These data show the promise of our Pro-XTEN protease-cleavable masking technology and showcase the work we did to select our preferred protease-cleavable linker, which indicates significant stability in circulation and healthy tissues, and efficient cleavage in tumors,” said Angie You, Ph.D., Chief Executive Officer of Amunix. “We are excited about the potential of this technology to improve the therapeutic indices for both T cell engagers and cytokines, and we are building a pipeline using this modular, plug and play technology.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?